Actively Recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Led by Iovance Biotherapeutics, Inc. · Updated on 2025-10-30
60
Participants Needed
12
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
CONDITIONS
Official Title
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed endometrial carcinoma, including carcinosarcoma; uterine sarcoma excluded
- Received 1 to 4 prior systemic therapy lines, with no more than 2 lines of chemotherapy
- Prior treatment with platinum-based chemotherapy and anti-PD-1/PD-L1 therapy
- Documented disease progression, treatment intolerance, or tumor growth after last therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and life expectancy over 6 months
- At least one resectable lesion and one measurable lesion for tumor-infiltrating lymphocyte generation
- Adequate organ and cardiopulmonary function
- Willingness to use highly effective birth control during treatment and up to 12 months after
- Participants over 70 years may enroll after discussion with the medical monitor
You will not qualify if you...
- Symptomatic untreated brain metastases
- History of allogeneic organ transplant or cell therapy with conditioning chemotherapy within past 20 years
- Requirement for systemic steroid therapy over 10 mg/day prednisone or equivalent
- Presence of any primary immunodeficiency
- Another primary cancer diagnosed within the last 3 years
- Receipt or planned receipt of live or attenuated vaccination within 28 days prior to study start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Honor Health
Phoenix, Arizona, United States, 85016
Actively Recruiting
2
University of Southern California
Los Angeles, California, United States, 90007
Actively Recruiting
3
Orlando Health
Orlando, Florida, United States, 32806
Actively Recruiting
4
H. Lee Moffitt Cancer Center and Research Institute, Inc.
Tampa, Florida, United States, 33612
Actively Recruiting
5
Augusta University
Augusta, Georgia, United States, 30912
Actively Recruiting
6
UofL Health - Brown Cancer Center
Louisville, Kentucky, United States, 40202
Actively Recruiting
7
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan, United States, 48201
Actively Recruiting
8
Roswell Park Cancer Institute
Buffalo, New York, United States, 14203
Actively Recruiting
9
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73117
Actively Recruiting
10
Allegheny Health
Pittsburgh, Pennsylvania, United States, 15524
Actively Recruiting
11
Avera Medical Group Oncology
Sioux Falls, South Dakota, United States, 57105
Actively Recruiting
12
MD Anderson Cancer Center - U of Texas
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
I
Iovance Biotherapeutics Study Team
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here